抗体

山羊抗纤维母细胞生长因子受体2抗体

MBS421759

0.1毫克

300美元

多克隆

山羊

未共轭

人类, 小鼠, 大鼠, 狗, 牛

免疫印迹, 酶免疫法

抗体

山羊抗纤维母细胞生长因子受体2抗体

纤维母细胞生长因子受体2

FGFR2; fibroblast growth factor receptor 2; BEK; BFR-1; CD332; CEK3; CFD1; ECT1; FLJ98662; JWS; K-SAM; KGFR; TK14; TK25; BEK fibroblast growth factor receptor; FGF receptor; FGFR-2; bacteria-expressed kinase; hydroxyaryl-protein kinase; keratinocyte grow; FGFR2 antibody; fibroblast growth factor receptor 2 (bacteria-expressed kinase; keratinocyte growth factor receptor; craniofacial dysostosis 1; Crouzon syndrome; Pfeiffer syndrome; Jackson-Weiss syndrome) antibody; BEK antibody; BFR-1 antibody; CD332 antibody; CEK3 antibody; CFD1 antibody; ECT1 antibody; JWS antibody; K-SAM antibody

fibroblast growth factor receptor 2 isoform 1; Fibroblast growth factor receptor 2; fibroblast growth factor receptor 2; fibroblast growth factor receptor 2; K-sam; KGFR; Keratinocyte growth factor receptor; CD_antigen: CD332

纤维母细胞生长因子受体2

纤维母细胞生长因子受体2;纤维母细胞生长因子受体2;BEK;JWS;BBDS;CEK3;CFD1;ECT1;KGFR;TK14;TK25;BFR-1;CD332;K-SAM;BEK;KGFR;KSAM;FGFR-2;KGFR

FGFR2_HUMAN

多克隆

山羊

Tested: Human; Expected from sequence similarity: Human, Mouse, Rat, Dog, Pig, Cow

821

GREKEITASPDY

通过硫酸铵沉淀和用免疫多肽抗原亲和层析从山羊血清中纯化得到的

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

肽酶联免疫吸附测定(EIA), 免疫印迹(免疫印迹)

Peptide ELISA: Antibody detection limit dilution 1: 64000. Western Blot: Approx 100kDa band observed in Human lysates of cell line A549 (calculated MW of 92. 0kDa according to NP_000132.1 and of 92.1kDa according to NP_075259.2). Recommended concentration: 0.3-1ug/ml.

Immunogen: Peptide with sequence C-GREKEITASPDY, from the internal region of the protein sequence according to NP_000132.3; NP_075259.4; NP_001138385.1; NP_001138386.1; NP_001138387.1; NP_001138388.1; NP_001138390.1; NP_001138391.1. Epitope: Internal region

Note: This antibody is expected to recognise all reported isoforms except isoform 7 (NP_001138389.1). The immunizing peptide represents part of the extracellular domain.

221316639

NP_000132.3

NM_000141.4

79,833 Da

ARMS-mediated Activation Pathway (1269471); Activated Point Mutants Of FGFR2 Pathway (1268871); Adaptive Immune System Pathway (1269171); Angiogenesis Pathway (198772); Axon Guidance Pathway (1270303); Central Carbon Metabolism In Cancer Pathway (1059538); Central Carbon Metabolism In Cancer Pathway (1084231); Constitutive Signaling By Aberrant PI3K In Cancer Pathway (1268880); Cytokine Signaling In Immune System Pathway (1269310); DAP12 Interactions Pathway (1269283)

The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009]

FGFR2: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with many craniosynostotic syndromes and bone malformations. Mutations cause syndromes with defects in facial and limb development, including Crouzon syndrome, Beare-Stevenson cutis gyrata syndrome, Pfeiffer syndrome, Apert syndrome, and Jackson-Weiss syndrome. Somatic mutations seen in gastric cancer. Amplified in gastric, breast and some B cell cancers, but deleted in glioblastoma Twenty splice-variant isoforms have been described. Protein type: EC 2.7.10.1; Protein kinase, TK; Kinase, protein; Membrane protein, integral; Protein kinase, tyrosine (receptor); Oncoprotein; TK group; FGFR family. Chromosomal Location of Human Ortholog: 10q26. Cellular Component: cell cortex; cell surface; cytoplasm; cytoplasmic membrane-bound vesicle; excitatory synapse; extracellular matrix; extracellular region; Golgi apparatus; integral to membrane; integral to plasma membrane; intracellular membrane-bound organelle; membrane; nucleoplasm; nucleus; plasma membrane. Molecular Function: 1-phosphatidylinositol-3-kinase activity; ATP binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; heparin binding; phosphatidylinositol-4,5-bisphosphate 3-kinase activity; protein binding; protein homodimerization activity; protein-tyrosine kinase activity; Ras guanyl-nucleotide exchange factor activity. Biological Process: alveolus development; angiogenesis; apoptosis; axonogenesis; bone mineralization; branching morphogenesis of a nerve; cell fate commitment; cell-cell signaling; embryonic cranial skeleton morphogenesis; embryonic digestive tract morphogenesis; embryonic organ development; embryonic organ morphogenesis; embryonic pattern specification; epidermis morphogenesis; epithelial cell differentiation; epithelial to mesenchymal transition; fibroblast growth factor receptor signaling pathway; gland morphogenesis; gut development; hair follicle morphogenesis; in utero embryonic development; inner ear morphogenesis; lacrimal gland development; limb bud formation; lung development; MAPKKK cascade; mesenchymal cell differentiation; mesodermal cell differentiation; midbrain development; morphogenesis of embryonic epithelium; multicellular organism growth; negative regulation of epithelial cell proliferation; negative regulation of transcription from RNA polymerase II promoter; neuroblast division in the ventricular zone; odontogenesis; orbitofrontal cortex development; organ growth; organ morphogenesis; otic vesicle formation; peptidyl-tyrosine phosphorylation; phosphoinositide phosphorylation; phosphoinositide-mediated signaling; positive regulation of cardiac muscle cell proliferation; positive regulation of cell cycle; positive regulation of cell division; positive regulation of cell proliferation; positive regulation of epithelial cell proliferation; positive regulation of GTPase activity; positive regulation of MAPKKK cascade; positive regulation of mesenchymal cell proliferation; positive regulation of smooth muscle cell proliferation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of Wnt receptor signaling pathway; post-embryonic development; protein amino acid autophosphorylation; pyramidal neuron development; regulation of cell fate commitment; regulation of fibroblast growth factor receptor signaling pathway; regulation of multicellular organism growth; regulation of osteoblast differentiation; regulation of osteoblast proliferation; regulation of phosphoinositide 3-kinase cascade; regulation of smooth muscle cell differentiation; regulation of smoothened signaling pathway; reproductive structure development; skeletal morphogenesis; ureteric bud development; ventricular cardiac muscle morphogenesis. Disease: Antley-bixler Syndrome Without Genital Anomalies Or Disordered Steroidogenesis; Apert Syndrome; Beare-stevenson Cutis Gyrata Syndrome; Bent Bone Dysplasia Syndrome; Crouzon Syndrome; Gastric Cancer; Jackson-weiss Syndrome; Lacrimoauriculodentodigital Syndrome; Pfeiffer Syndrome; Saethre-chotzen Syndrome; Scaphocephaly, Maxillary Retrusion, And Mental Retardation

0.1毫克

300美元